Clinical trials: Low Dose
Malignant Melanoma
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
The purpose of the study is to test safety and efficacy of different doses of thymosin alpha 1 (1.6 mg, 3.2 mg, and 6.4 mg) in combination with dacarbazine and with or without Interferon alpha in treating patients affected by…
- Trial name
- NCT00911443
- Testing
- Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg, Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg, Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg
- Where
- 64 sites in France, Germany and 6 more
- Volunteers
- 488 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST 2 (NCT00442325)
- Testing
- Atorvastatin (Lipitor)
- Where
- 32 sites in Greece, Hungary and 6 more
- Volunteers
- 595 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Asthma
Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
Primary objective The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory…
- Trial name
- ELITRA (NCT02296411)
- Testing
- CHF 5259 12.5 µg + Qvar
- Where
- 28 sites in Bulgaria, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pneumonia
Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
This is an investigator sponsored double-blinded, multinational, multi center, randomized (2:1 active:placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating…
- Trial name
- NCT01532544
- Testing
- Ilomedin and Integrilin, low molecular weight heparin.
- Where
- 4 sites in Denmark, Finland
- Volunteers
- 5 people
- Sponsor
- Thrombologic ApS
Lung Cancer
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
- Trial name
- NCT04968548
- Testing
- Blood collection
- Where
- 31 sites in United States, Canada
- Volunteers
- 6,182 people
- Sponsor
- Nucleix Ltd.
Myelodysplastic Syndrome
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
This protocol is a follow-up for patients receiving continuation of OPN-305 monotherapy treatment or combination treatment with azacitidine after completion of the dose confirming, dose expansion and HMA naïve parts of the main…
- Trial name
- NCT03337451
- Testing
- OPN-305
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Opsona Therapeutics Ltd.
Dysmenorrhea
Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea
The purpose of this study is to determine whether combination oral contraceptive pill of Norethindrone \& Ethinyl estradiol is effective in the treatment of dysmenorrhea associated with endometriosis.
- Trial name
- NCT00212342
- Testing
- Norethisterone,Ethinylestradiol, Sugar pill
- Volunteers
- 100 people
- Sponsor
- Nobelpharma
Dyslipidemias
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
- Trial name
- LA ATGOAL (NCT00645151)
- Testing
- Atorvastatin
- Where
- 33 sites in Brazil, Chile and 6 more
- Volunteers
- 512 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Multiple Myeloma, Relapsed Cancer
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease
- Trial name
- NCT05641324
- Testing
- ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 4 people
- Sponsor
- Anaveon AG
Multiple Myeloma
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory…
- Trial name
- STRATUS (NCT01712789)
- Testing
- Pomalidomide, Dexamethasone
- Where
- 112 sites in Austria, Belgium and 18 more
- Volunteers
- 682 people
- Sponsor
- Celgene
Pre-Eclampsia
Low Dose Aspirin for Prevention of Early Pregnancy Loss
Preeclampsia is a pregnancy-specific, multisystem disorder affecting 3% to 8% of pregnancies and remains a significant cause of maternal and neonatal morbidity and mortality worldwide.
- Trial name
- NCT06261203
- Testing
- Aspirin
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Egymedicalpedia
Prevention
Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from…
- Trial name
- NCT01069939
- Testing
- Esomeprazole
- Where
- 46 sites in Japan, South Korea and 1 more
- Volunteers
- 427 people
- Sponsor
- AstraZeneca
Acute Low Back Pain
A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day
The primary objective of this study is to determine the time of onset of analgesic effect of Tramadol Contramid® Once-A-Day (OAD) in acute low back pain.
- Trial name
- NCT00952068
- Testing
- Tramadol Contramid® OAD 200mg
- Volunteers
- 47 people
- Sponsor
- Labopharm Inc.
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
The primary objective of this study to examine the long-term safety of rabeprazole 5 mg or 10 mg tablets administered once daily in participants who were confirmed to have no recurrence of gastric or duodenal ulcer by endoscopic…
- Trial name
- NCT01398410
- Testing
- Rabeprazole
- Where
- 50 sites in Japan
- Volunteers
- 405 people
- Sponsor
- Eisai Co., Ltd.
Dyslipidemia
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia.
- Trial name
- PURSUIT (NCT06173570)
- Testing
- AZD0780
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 428 people
- Sponsor
- AstraZeneca
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360047
- Where
- Spain
- Volunteers
- 39,513 people
- Sponsor
- AstraZeneca
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603278
- Testing
- GW685698X
- Where
- 155 sites in United States, Canada and 11 more
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Glucose, Low Blood, Glucose, High Blood
Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC
The objective of this study is to test two different operating modes of the latest version of the Dose Safety artificial pancreas system (APS), the Dose Safety Controller (DSC version 2.3), in a population of subjects with type 1…
- Trial name
- NCT03428295
- Testing
- Dose Safety AP system
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dose Safety Inc.
Prostatic Neoplasms
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
The monoclonal antibody J591 is being investigated as therapy for patients with prostate cancer, in combination with recombinant interleukin-2 (Proleukin, Aldesleukin).
- Trial name
- NCT00040586
- Testing
- Monoclonal Antibody J591, Recombinant Interleukin-2
- Where
- United States
- Sponsor
- BZL Biologics
Colon Cancer
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any…
- Trial name
- NCT00675012
- Testing
- NGR-hTNF, Oxaliplatin, capecitabine
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- AGC Biologics S.p.A.